Everything below concerns Prohibited list. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-13. Numbers and descriptions here follow the published literature rather than marketing material.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ | Nuclear receptor; not androgen receptor |
| Studied indications | Dyslipidemia; obesity; diabetes | Early clinical research; development discontinued |
| Rodent toxicity | Tumor formation in multiple tissues | Dose-dependent findings in some studies |
| Human approval | None | No approved therapeutic use |
| Typical analytical method | LC-MS/MS | Used for identity and quantification |
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
== Triquinoyl therapy == In the late 1940s, William J. Hale claimed that "triquinoyl", being a trimer of William Frederick Koch's glyoxylide, should be just as effective as the latter against "diabetes, arthritis, poliomyelitis, and even cancer". Even though there is no research supporting this claim (and Koch's glyoxylide preparations were found to be just distilled water), triquinoyl is still listed as an ingredient of some alternative medicine remedies.
The current reviewers identified a number of basic science research areas that could be helpful in resolving some of the controversies in the field, two of which were: 1) material science aspects of deuterated metals using modern characterization techniques, and 2) the study of particles reportedly emitted from deuterated foils using state-of-the-art apparatus and methods. The reviewers believed that this field would benefit from the peer-review processes associated with proposal submission to agencies and paper submission to archival journals. Cold fusion researchers placed a "rosier spin" on the report, noting that they were finally being treated like normal scientists, and that the report had increased interest in the field and caused "a huge upswing in interest in funding cold fusion research". However, in a 2009 BBC article on an American Chemical Society's meeting on cold fusion, particle physicist Frank Close was quoted stating that the problems that plagued the original cold fusion announcement were still happening: results from studies are still not being independently verified and inexplicable phenomena encountered are being labelled as "cold fusion" even if they are not, in order to attract the attention of journalists. In February 2012, millionaire Sidney Kimmel, convinced that cold fusion was worth investing in by a 19 April 2009 interview with physicist Robert Duncan on the US news show 60 Minutes, made a grant of $5.5 million to the University of Missouri to establish the Sidney Kimmel Institute for Nuclear Renaissance (SKINR).
== Chimerism and intersex == The concept of a "human hermaphrodite" resulting from chimerism is largely a misconception. Most intersex individuals are not chimeras, and most human chimeras are not observed to have intersex traits. Theoretically, if a gynandromorphic human chimera were to have fully functioning male and female gonad tissue, such an individual could self-fertilize; this hypothesis is backed by the fact that hermaphroditic animal species commonly reproduce in this way, and it has been observed in a rabbit. However, no such case of functional self-fertilization has ever been documented in humans; and it is non-existent or extremely rare in mammals, especially in humans. While humans are known to have sex characteristics that diverge from typical males or typical females, these individuals fall under the social umbrella of intersex conditions and traits, and some consider the term "hermaphrodite" to be a slur when applied to them.
Sources: en.wikipedia.org
In 1998 the BPL began sourcing its plasma from the United States due to concerns over vCJD in the UK. In 2002 the Department of Health (DoH) formed DCI Biologicals Inc to purchase US company Life Resources Inc to supply all of the BPL's plasma. BPL became an operating division within new special health authority, NHS Blood and Transplant, in 2005. This placed BPL alongside the National Blood Service and the organ transplant division, a strategic partnership to safeguard blood, tissues and blood products. On 31 December 2010 the BPL was vested into a limited company, Bio Products Laboratory Ltd, and ownership transferred to the DoH, with BPL Ltd and DCI Biologicals Inc brought under the same DoH holding company, Plasma Resources UK Ltd. On 18 July 2013 it was announced by Business Secretary Vince Cable that Bain Capital had bought 80% of Plasma Resources UK (PRUK) from the DoH for £230m, which included both BPL and DCI Biologicals. The company was subsequently renamed BPL Holdings, with the original BPL site now called BPL Therapeutics and DCI named BPL Plasma. In 2018, when it was the sole owner, the Chinese group Creat had announced that it planned to integrate BPL's operations with German plasma product manufacturer Biotest. In 2022, Creat was required to dispose of its U.S. plasma centers which necessitated a sale of BPL as a whole. The sale was made to Kedrion BioPharma and BPL became a subsidiary of the Kedrion Group.
==== MeSH D08.811.600 – multienzyme complexes ==== MeSH D08.811.600.075 – anthranilate phosphoribosyltransferase MeSH D08.811.600.085 – anthranilate synthase MeSH D08.811.600.116 – aspartate carbamoyltransferase MeSH D08.811.600.130 – aspartokinase homoserine dehydrogenase MeSH D08.811.600.200 – cholesterol side-chain cleavage enzyme MeSH D08.811.600.250 – electron transport chain complex proteins MeSH D08.811.600.250.500 – electron-transferring flavoproteins MeSH D08.811.600.250.500.500 – electron transport complex i MeSH D08.811.600.250.500.750 – electron transport complex ii MeSH D08.811.600.250.500.750.500 – succinate dehydrogenase MeSH D08.811.600.250.687 – electron transport complex iv MeSH D08.811.600.250.875 – succinate cytochrome c oxidoreductase MeSH D08.811.600.250.875.249 – electron transport complex ii MeSH D08.811.600.250.875.249.500 – succinate dehydrogenase MeSH D08.811.600.250.875.500 – electron transport complex iii MeSH D08.811.600.317 – fatty acid synthetase complex MeSH D08.811.600.391 – glycine decarboxylase complex MeSH D08.811.600.391.100 – aminomethyltransferase MeSH D08.811.600.391.150 – dihydrolipoamide dehydrogenase MeSH D08.811.600.391.175 – glycine decarboxylase complex h-protein MeSH D08.811.600.391.200 – glycine dehydrogenase (decarboxylating) MeSH D08.811.600.465 – ketoglutarate dehydrogenase complex MeSH D08.811.600.465.500 – dihydrolipoamide dehydrogenase MeSH D08.811.600.541 – lactose synthase MeSH D08.811.600.700 – phosphoenolpyruvate sugar phosphotransferase system MeSH D08.811.600.710 – photosynthetic reaction center complex proteins MeSH D08.811.600.710.249 – light-harvesting protein complexes MeSH D08.811.600.710.374 – cytochrome b6f complex MeSH D08.811.600.710.374.500 – cytochromes b6 MeSH D08.811.600.710.374.750 – cytochromes f MeSH D08.811.600.710.374.875 – plastoquinol-plastocyanin reductase MeSH D08.811.600.710.500 – photosystem i protein complex MeSH D08.811.600.710.750 – photosystem ii protein complex MeSH D08.811.600.715 – polyketide synthases MeSH D08.811.600.720 – prostaglandin-endoperoxide synthases MeSH D08.811.600.720.500 – cyclooxygenase 1 MeSH D08.811.600.720.750 – cyclooxygenase 2 MeSH D08.811.600.730 – proteasome endopeptidase complex MeSH D08.811.600.741 – pyruvate dehydrogenase complex MeSH D08.811.600.741.525 – dihydrolipoamide dehydrogenase MeSH D08.811.600.741.625 – dihydrolipoyllysine-residue acetyltransferase MeSH D08.811.600.741.725 – pyruvate dehydrogenase (lipoamide) MeSH D08.811.600.850 – sucrase-isomaltase complex MeSH D08.811.600.896 – tryptophan synthase
=== Medium of instruction === At primary and secondary school levels, the government maintains a policy of "mother tongue instruction"; most schools use Cantonese as the medium of instruction, with written education in both Chinese and English. Other languages being used as the medium of instruction in non-international school education include English and Putonghua (Mandarin Chinese). Secondary schools emphasise "bi-literacy and tri-lingualism", which has encouraged the proliferation of spoken Mandarin language education. English is the official medium of instruction and assessment for most university programmes in Hong Kong, although Cantonese is predominant in informal discussions among local students and professors.
=== Air === Manchester Airport lies just 4 miles (6.4 km) along the A538 to the north-west, but Wilmslow lies away from the approach and departure routes; it therefore does not suffer from aircraft noise as Hale Barns and Heald Green do.
Sources: en.wikipedia.org
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.
Rodent studies found dose-dependent tumors in several organs. The sponsor discontinued the program over cancer concerns. Human risk from long-term use remains unknown.
Controlled human endurance trials are lacking. Animal studies show increased exercise capacity under some conditions. Anecdotal reports are not equivalent to clinical evidence.
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.